These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29721072)

  • 21. Adhesion GPCR ADGRE2 Maintains Proteostasis to Promote Progression in Acute Myeloid Leukemia.
    Huang D; Yu Z; Lu H; Jiang P; Qian X; Han Y; Qian P
    Cancer Res; 2024 Jul; 84(13):2090-2108. PubMed ID: 39082681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.
    Wu D; Wang W; Chen W; Lian F; Lang L; Huang Y; Xu Y; Zhang N; Chen Y; Liu M; Nussinov R; Cheng F; Lu W; Huang J
    Haematologica; 2018 Sep; 103(9):1472-1483. PubMed ID: 29880605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WNT inhibitory factor 1 (WIF1) is a novel fusion partner of RUNX family transcription factor 1 (RUNX1) in acute myeloid leukemia with t(12;21)(q14;q22).
    Yang S; Sun M; Chen L; Zhang H; Sun L; Liu E; Tian X; Hou X; Lin Y; Lu M
    J Hematop; 2024 Jul; ():. PubMed ID: 39066949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression.
    Toscan CE; Jing D; Mayoh C; Lock RB
    Br J Cancer; 2020 Jun; 122(12):1769-1781. PubMed ID: 32242100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.
    Greenblatt SM; Man N; Hamard PJ; Asai T; Karl D; Martinez C; Bilbao D; Stathias V; Jermakowicz AM; Duffort S; Tadi M; Blumenthal E; Newman S; Vu L; Xu Y; Liu F; Schurer SC; McCabe MT; Kruger RG; Xu M; Yang FC; Tenen DG; Watts J; Vega F; Nimer SD
    Cancer Cell; 2018 Jun; 33(6):1111-1127.e5. PubMed ID: 29894694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia.
    Sahasrabudhe DM; Liesveld JL; Minhajuddin M; Singh NA; Nath S; Kumar VM; Balys M; Evans AG; Azadniv M; Hansen JN; Becker MW; Sharon A; Thomas VK; Moore RG; Khera MK; Jordan CT; Singh RK
    Sci Rep; 2024 Jun; 14(1):12868. PubMed ID: 38834690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapy for fusion-driven high-risk acute leukemia.
    Pikman Y; Stegmaier K
    Blood; 2018 Sep; 132(12):1241-1247. PubMed ID: 30049809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells.
    Martinez N; Drescher B; Riehle H; Cullmann C; Vornlocher HP; Ganser A; Heil G; Nordheim A; Krauter J; Heidenreich O
    BMC Cancer; 2004 Aug; 4():44. PubMed ID: 15298716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic stem and progenitor cell membrane-coated vesicles for bone marrow-targeted leukaemia drug delivery.
    Li J; Wu H; Yu Z; Wang Q; Zeng X; Qian W; Lu S; Jiang L; Li J; Zhu M; Han Y; Gao J; Qian P
    Nat Commun; 2024 Jul; 15(1):5689. PubMed ID: 38971796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional Characterization of Cooperating MGA Mutations in RUNX1::RUNX1T1 Acute Myeloid Leukemia.
    Klco J; Thomas M; Qi W; Walsh M; Ma J; Westover T; Abdelhamed S; Ezzell L; Rolle C; Xiong E; Rosikiewicz W; Xu B; Pruett-Miller S; Loughran A; Janke L
    Res Sq; 2023 Sep; ():. PubMed ID: 37790524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted nanopore sequencing for the identification of ABCB1 promoter translocations in cancer.
    Williams MS; Basma NJ; Amaral FMR; Williams G; Weightman JP; Breitwieser W; Nelson L; Taylor SS; Wiseman DH; Somervaille TCP
    BMC Cancer; 2020 Nov; 20(1):1075. PubMed ID: 33167906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYB as a Critical Transcription Factor and Potential Therapeutic Target in AML.
    Clarke ML; Gabrielsen OS; Frampton J
    Adv Exp Med Biol; 2024; 1459():341-358. PubMed ID: 39017851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered
    Aitken MJL; Malaney P; Zhang X; Herbrich SM; Chan L; Benitez O; Rodriguez AG; Ma H; Jacamo R; Duan R; Link TM; Kornblau SM; Kanagal-Shamanna R; Bueso-Ramos CE; Post SM
    NAR Cancer; 2022 Dec; 4(4):zcac039. PubMed ID: 36518526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition.
    Lesovaya EA; Savinkova AV; Morozova OV; Lylova ES; Zhidkova EM; Kulikov EP; Kirsanov KI; Klopot A; Baida G; Yakubovskaya MG; Gordon LI; Readhead B; Dudley JT; Budunova I
    Mol Cancer Ther; 2020 Sep; 19(9):1898-1908. PubMed ID: 32546661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-genetic heterogeneity, altered cell fate and differentiation therapy.
    Lewis AC; Kats LM
    EMBO Mol Med; 2021 Mar; 13(3):e12670. PubMed ID: 33555144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible roles for glucocorticoid signalling in breast cancer.
    McNamara KM; Kannai A; Sasano H
    Mol Cell Endocrinol; 2018 May; 466():38-50. PubMed ID: 28687451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomics and transcriptomics analyses of ataxia telangiectasia cells treated with Dexamethasone.
    Menotta M; Orazi S; Gioacchini AM; Spapperi C; Ricci A; Chessa L; Magnani M
    PLoS One; 2018; 13(4):e0195388. PubMed ID: 29608596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trinh BQ, Ummarino S, Zhang Y, et al. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021;138(15):1331-1344.
    Blood; 2023 May; 141(20):2542. PubMed ID: 37200056
    [No Abstract]   [Full Text] [Related]  

  • 39. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.
    Martinez-Soria N; McKenzie L; Draper J; Ptasinska A; Issa H; Potluri S; Blair HJ; Pickin A; Isa A; Chin PS; Tirtakusuma R; Coleman D; Nakjang S; Assi S; Forster V; Reza M; Law E; Berry P; Mueller D; Osborne C; Elder A; Bomken SN; Pal D; Allan JM; Veal GJ; Cockerill PN; Wichmann C; Vormoor J; Lacaud G; Bonifer C; Heidenreich O
    Cancer Cell; 2019 Apr; 35(4):705. PubMed ID: 30991028
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular mechanisms of Y chromosome loss and
    Abumsimir B; Al-Qaisi T; Zein S
    Future Sci OA; 2024; 10(1):2340838. PubMed ID: 38817386
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.